Member Info for sajy

As some are wondering what the reason is for the rise in share price. Yesterday a delayed trade of about 2.4 Million shares appeared after hours. My guess is that Obotritia Capital KGaA has sold it's last lot and is now fully out. They were the seller over the last few months that had caused the drop. I was waiting for them to be out before I added more and it looks like others have done the same, hence the rise.

I can see the share price rising steadily over the next month a positions are taken in anticipation of an update on the in vivo data as promised by Iain in the recent presentation. Iain hinted that the data was looking very good, so I am expecting a very good update. This data will be sufficient to then begin discussions and hopefully sign a licensing deal.

Trying to get another 50K but had to put a trade plan in at 6.6. Not sure if it will get filled.

Wanted another 100K shares this morning but was NT. Had to buy in smaller amounts to get filled. Have added substantially over the last few days. Even after averaging down, currently underwater here but have brought my average down. I am one of the very few that still believes Rene will come good.

Expecting update on in vivo data in about 6 weeks and then enter licensing deal discussions with partner. Need that first licensing deal and then sentiment will change.

Just had a chat with IR.

Still on track to issue admission document before the end of June. Expect shares to start trading within 24hrs of issuing admission document.

Final results will also be announced before end of June and expect further info as to what is happening in Chad.

I have asked them to do a presentation via Investor Meet and they say it is very likely that will happen after the results have been announced.

The interim CEO Debra used to work at GSK, who are into Antimicrobial Resistance in a big way. Destiny looking for a partner for XF-73, very interesting.

Chairman confirmed today that company is in discussions with several partners at various stages regarding licensing of XF-73. He also confirmed company expecting a large upfront payment.

Also preclinical work on XF-73 in conjunction with NIAID is looking very good and expect announcement on this in couple of months.

Chairman has bought shares this morning on the open market.

Hi Komakino, this info is not from any articles but from someone I trust. He is pretty sure that is the current situation regarding the Chad assets. We were receiving the revenues and paying salaries but that has stopped now.

My understanding is that we are no longer receiving any revenues from our assets in Chad and therefore stopped paying the salaries of the employees. I cannot confirm 100% but I am pretty confident that is the case at present.

“(PASTEUR) Act, which would commit $6 billion to reinvigorate innovation in much needed R&D of new antimicrobials”.

Explains why NIAID is interested in XF-73 for US army. See below.

https://thepharmaletter.com/article/bipartisan-pasteur-act-to-fight-antimicrobial-resistance-reintroduced

Pfizer failure with SA4Ag vaccine in prevention of surgical infections highlight massive opportunity for Destiny Pharma’s XF-73 nasal gel. See link below

https://t.co/DMab5ckYyn

We all know how cheap Dest is at this price and that is why I have been buying. This reminds me of when I bought Avct at 20p and nobody was interested and then all of a sudden it came on the radar and went on to hit £2. I made a packet on that and I am very confident of doing the same here, it's only a matter of time.

Excellent video by Justin and I totally agree that Dest is ridiculously cheap at £30M Mcap. The upside is hugh as long as the management deliver and I think they will. I think we will get a decent upfront payment of about £10M for XF-73 and a major pharma as a partner. This is because I believe XF-73 will be used for every operation in the future and will become a blockbuster drug. Then add in £5M upfront for the rest of the world rights for M3 and we $19M of milestones for M3 from Sebela. That's about £30M incoming over the next 12-24 months, so no need for any further placings until both M3 and XF-73 get approved. I have built a substantial holding and expect several bags over the next couple of years.

Justin Waite and Vadim Alexandre discuss Dest and agree it is very cheap at current price. Vadim says he is interested in buying and that on completion of Xf-73 share price will pop. See link below, from 17 mins in.

https://www.voxmarkets.co.uk/articles/vadim-alexandre-discusses-polarean-imaging-destiny-pharma-eca6522

Destiny Pharma would like to say a big thank you to @MedNous (Evernow Publishing Ltd) for publishing such an in-depth article on the significant progress that we have made across both XF-73 and NTCD-M3. Click link for full article.

https://t.co/WSvLReNHgd

Bantham, depends what you mean by short term. I am expecting an update on Sporcov soon, that will show that the pre clinical results for influenza and covid are very good. Also in the next few months I expect an update on the pre clinical work on XF-73 funded by NIAID, again early indications are very good. I am hoping that in this update they will announce that NIAID have agreed pay for clinical trials, which will be a hugh endorsement for XF-73.

Agree with you Trek that Dest is very cheap at this price, when considering the following:

1. 2 phase 3 ready drugs, one licensed (M3) and in discussions to license the other (XF-73).
2. Management are expecting a Major pharma as a partner for XF-73 and are expecting a large upfront payment. This is because they believe XF-73 will become a blockbuster drug and in time it will be the standard of care for virtually every operation.
3. Managements confidence is backed up by the fact that NIAID are paying for pre clinical work on XF-73 for wounds for the USA army. Initial results are looking good. NIAID more than likely will pay for clinical trials also. This will be a hugh endorsement for XF-73.
4. Sporcov pre clinical results are excellent for Influenza and Covid. Expect an update on this soon.
5. Now that Sebela will pay for phase 3 trial for M3, Dest can use that data to gain approval in rest of the world without having to do another phase 3 trial. This is means the licensing deals we sign for rest of world with other partners will likely involve a decent upfront payment as they do not have to pay for a trial.

All the above for a Mcap of £29M, very undervalued indeed. I have a large holding and very confident that this will at least 10 bag from here over time, just need a little patience.

My reasons why PXC is a good investment :

1. Share price heavily smashed down due to delay in completing bond financing, was 44p on the 7th March, now 22p.
2. Rumors that Investors from the USA now interested in bond financing in addition to original investors, hence tweaking of terms to bring on board USA investors.
3. Rumors that in discussions to invest in a company already in production and generating profits.
4. On completion of the above can see PXC valued at around £80M Mcap, which is several bags from here.

Iain has done what he said, bought 400k in total now. Lets hope he is true to his word when he says we going to sign deals this year.

It is quite clear now that in addition to the original cornerstone investors, we also have a group of investors from the USA now interested. Hint is that US interest rates have gone up and tweaking of the terms to bring on board these investors.
The bit about other exciting stuff is hinting at investing in a producing asset I think. Just my thoughts but I could be wrong.

What StanleyUk has posted makes sense. The tweaking of the terms of the bond financing must be to bring onboard the stateside investors. As this has now been made public, the cornerstone investors will be under pressure to complete asap, otherwise PXC will go with the stateside investors. This ties in with the fact that the loan was taken for such a short period ( 3 months) as the management know they have a choice of investors and one of them is likely to complete fairly soon.